Lexicon seeks U.K. approval for study of LX6171 in cognitive disorders

By Lisa Kerner

Charlotte, N.C., June 29 - Lexicon Genetics Inc. submitted a Clinical Trial Authorization filing to the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) for LX6171, a small molecule compound for cognitive disorders such as Alzheimer's disease, schizophrenia, vascular dementia, attention deficit disorder and Fragile X syndrome.

The company said it plants to begin a phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of LX6171 following MHRA clearance.

Preclinical studies have shown LX6171 improves learning and memory in healthy and aged mice.

LX6171 targets a membrane protein expressed in the central nervous system. Mice lacking the protein displayed improved performance in tests of learning and memory, even after aging, according to a company news release.

Lexicon is a biopharmaceutical company located in The Woodlands, Texas.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.